CytRx Corporation (CYTR)
| Previous close | 3.1800 |
| Open | 3.1800 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1000 |
| Day's range | 2.8200 - 3.5000 |
| 52-week range | 0.3500 - 5.0000 |
| Volume | 121,226 |
| Avg. volume | 243,863 |
| Market cap | 126.586M |
| Beta (5Y monthly) | 2.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2440 |
| Earnings date | 16 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
CytRx Highlights Orphazyme’s Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") has announced the appointment of Christophe Bourdon as its new Chief Executive Officer, effective as of April 1, 2021. This appointment comes as Orphazyme awaits potential Food and Drug Administration ("FDA") approval of arimoclomol for the treatment of Niemann-Pick disease Type C ("NPC"). CytRx has an agreement with Orphazyme that can yield potential milestone payments and future single and double-digit royalties paid on sales of arimoclomol.
- Business Wire
CytRx to Participate in Upcoming Investor Conferences
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, is scheduled to participate in the following upcoming conferences:
- Business Wire
CytRx is Added to the LD Micro Index
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it is now a part of the LD Micro Index (the "Index").
